TSHA on Nasdaq

Taysha Gene Therapies, Inc.

We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with CURIS INC, Alpha Cognition Inc. or TScan Therapeutics, Inc., or pick any stock.

  • TickerTSHA on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersDallas, Texas1
  • Incorporated inDE2
  • Business address3000 Pegasus Park Drive, Suite 1430, Dallas, Tx 752472
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, we aim to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. Our management team has proven experience in gene therapy development and commercialization. We leverage this experience, our manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-1130.6%Operating margin4
-1115.3%Net margin4
17.3%Revenue growth, 20254
-44.1%Return on equity4
0.20×Debt to equity4
-$93.8MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$86.4M

Out of $9.8M in revenue.4 The company lost money this year.

Financial statements

Revenue564$9.8M in 2025+291% since 2022
0$5.0M$10.0M$15.0M$20.0M2022: $2.5M$2.5M20222023: $15.5M$15.5M2023+518%2024: $8.3M$8.3M2024−46%2025: $9.8M$9.8M2025+17%
Operating income78564-$110.5M in 2025+157% since 2020
-$200.0M-$150.0M-$100.0M-$50.0M02020: -$43.0M-$43.0M20202021: -$173.3M-$173.3M2021+303%2022: -$162.4M-$162.4M2022−6%2023: -$72.4M-$72.4M2023−55%2024: -$91.5M-$91.5M2024+26%2025: -$110.5M-$110.5M2025+21%
Net income78564-$109.0M in 2025+82% since 2020
-$200.0M-$150.0M-$100.0M-$50.0M02020: -$60.0M-$60.0M20202021: -$174.5M-$174.5M2021+191%2022: -$166.0M-$166.0M2022−5%2023: -$111.6M-$111.6M2023−33%2024: -$89.3M-$89.3M2024−20%2025: -$109.0M-$109.0M2025+22%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenue$9.8M$8.3M
Research and development$86.4M$66.0M
General and administrative$33.9M$29.0M
Impairment of long-lived assets$0$4.8M
Total operating expenses$120.3M$99.8M
Loss from operations-$110.5M-$91.5M
Change in fair value of warrant liability-$1.2M$16.0K
Change in fair value of term loan-$6.2M-$4.6M
Interest income$9.2M$6.9M
Interest expense-$63.0K-$102.0K
Other expense-$291.0K-$110.0K
Total other income, net$1.5M$2.2M
Net loss-$109.0M-$89.3M
Net loss per common share, basic-$0.34-$0.36
Net loss per common share, diluted-$0.34-$0.36
Weighted average common shares outstanding, basic319.7M shares250.1M shares
Weighted average common shares outstanding, diluted319.7M shares250.1M shares

Compare Taysha Gene Therapies, Inc. with another company

Leadership

Who has led Taysha Gene Therapies, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. R.a. Session Ii.2020–2022
  2. Sean P. Nolan2023–now

President

  1. R.a. Session Ii.2020–2022
  2. Sukumar Nagendran2023–now
2025
Board members and other officers (10)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerKamran P. Alam named Nov 7, 2022 to Aug 25, 202324
  • Executive Officer, DirectorRA Session II named Nov 7, 202225

Timeline

  1. Jan 4, 2023New chief executive Sean P. Nolan becomes CEO12
  2. Sep 23, 2020New chief executive R.a. Session Ii. becomes CEO13

Filings

305 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 65 major events, 85 insider forms, 44 large holders, 2 private raises, 88 other. The latest 20:

  1. Aug 14, 2026SCHEDULE 13G/A EDGAR
  2. Aug 13, 2026SCHEDULE 13G/A EDGAR
  3. Aug 11, 202610-Q EDGAR
  4. Aug 11, 20268-K EDGAR
  5. Jul 10, 2026144 EDGAR
  6. Jul 10, 20264 EDGAR
  7. Jun 25, 20268-K EDGAR
  8. Jun 25, 2026424B5 EDGAR
  9. Jun 24, 2026424B5 EDGAR
  10. Jun 22, 20268-K EDGAR
  11. Jun 2, 20264 EDGAR
  12. Jun 2, 20264 EDGAR
  13. Jun 2, 20264 EDGAR
  14. Jun 2, 20264 EDGAR
  15. Jun 2, 20268-K EDGAR
  16. May 15, 2026SCHEDULE 13G/A EDGAR
  17. May 15, 2026SCHEDULE 13G/A EDGAR
  18. May 6, 202610-Q EDGAR
  19. May 6, 20268-K EDGAR
  20. Apr 22, 2026ARS EDGAR

The 305 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

47 open-market trades by officers, directors and large owners since October 2021: 16 buys and 31 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 10, 2026Nagendran SukumarPresident and Head of R&DSale200,000$6.24$1.2MForm 4
Apr 10, 2026Nagendran SukumarPresident and Head of R&DSale200,000$4.46$892.0KForm 4
Feb 4, 2026Alam KamranCHIEF FINANCIAL OFFICERSale1,655$4.52$7.5KForm 4
Jan 26, 2026Alam KamranCHIEF FINANCIAL OFFICERSale23,849$4.61$109.9KForm 4
Jan 26, 2026Nagendran SukumarPresident and Head of R&DSale26,918$4.61$124.1KForm 4
Jan 26, 2026Nolan Sean P.Chief Executive OfficerSale41,312$4.61$190.4KForm 4
Jan 23, 2026Alam KamranCHIEF FINANCIAL OFFICERSale78,968$4.75$375.1KForm 4
Jan 23, 2026Nagendran SukumarPresident and Head of R&DSale89,132$4.75$423.4KForm 4
Jan 23, 2026Nolan Sean P.Chief Executive OfficerSale136,789$4.75$649.7KForm 4
Jan 12, 2026Nagendran SukumarPresident and Head of R&DSale200,000$4.71$942.0KForm 4
Dec 1, 2025Nagendran SukumarPresident and Head of R&DSale260,047$4.51$1.2MForm 4
Nov 28, 2025Nagendran SukumarPresident and Head of R&DSale110,125$4.75$523.1KForm 4
Sep 10, 2025Nagendran SukumarPresident and Head of R&DSale200,000$3.23$646.0KForm 4
Aug 21, 2025Nagendran SukumarPresident and Head of R&DSale57,054$2.85$162.6KForm 4
Aug 21, 2025Alam KamranCHIEF FINANCIAL OFFICERSale54,491$2.85$155.3KForm 4
May 30, 2025Manning Paul B10% ownerBuy750,000$2.75$2.1MForm 4
Jun 27, 2024Manning Paul B10% ownerBuy1,333,333$2.25$3.0MForm 4
Nov 17, 2023Manning Paul B10% ownerBuy100,000$1.63$163.0KForm 4
Aug 24, 2023Alam KamranCHIEF FINANCIAL OFFICERSale33,000$2.33$76.9KForm 4
Aug 16, 2023Manning Paul B10% ownerBuy16,466,667$0.90$14.8MForm 4

All 47 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Aug 16, 2023Raised $150 million in a private offering of equity Form D: $150 million offered in all Form D
  2. Oct 21, 2022Raised $30 million in a private offering of equity Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Avoro Capital Advisors LLC23,888,888$162.7M1.5%+2,188,888
Ra Capital Management, L.P.23,555,648$160.4M1.4%No change
Goldman Sachs Group Inc22,713,118$154.7M0.0%+343,473
BlackRock, Inc.20,691,927$140.9M0.0%+2,326,319
Vestal Point Capital, LP19,415,000$132.2M3.1%+1,415,000
Morgan Stanley16,487,479$112.3M0.0%−1,477,892
Rtw Investments, LP13,560,258$92.3M0.8%−119,990
Fmr LLC13,336,413$90.8M0.0%−984,842
Vanguard Capital Management LLC12,478,595$85.0M0.0%+2,247,093
State Street Corp11,421,920$77.8M0.0%+212,842
Siren, L.L.C.9,846,579$67.1M1.4%+1,016,666
Octagon Capital Advisors LP9,693,244$66.0M6.1%+833,333
Geode Capital Management, LLC6,560,394$44.7M0.0%+1,028,439
Polar Capital Holdings Plc5,117,133$34.8M0.1%−537,207
Mpm Bioimpact LLC4,500,000$30.6M1.9%New
D. E. Shaw & Co., Inc.4,398,652$30.0M0.0%−28,649
Baker Bros. Advisors LP4,004,756$27.3M0.1%No change
Wellington Management Group Llp3,975,605$27.1M0.0%+3,349,244
Healthcare Of Ontario Pension Plan Trust Fund3,885,501$26.5M0.0%+1,002,200
GordonMD Global Investments LP723,185$24.5M11.9%−14,365
Casdin Capital, LLC3,250,000$22.1M1.1%No change
Vanguard Portfolio Management LLC3,140,009$21.4M0.0%+1,117,511
ADAR1 Capital Management, LLC3,040,466$20.7M1.0%+61,037
Pictet Asset Management Holding SA2,770,701$18.9M0.0%+2,751,383
Aberdeen Group plc2,327,152$15.8M0.0%+1,306,089

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38